Journal of Vaccines & Vaccination

Herd Immunity and Its Role in Controlling Infectious Diseases

Jeniffer Müller ^* Department of Epidemiology, Heidelberg University, Heidelberg, Germany
^*Correspondence: Jeniffer Müller, Department of Epidemiology, Heidelberg University, Heidelberg, Germany, Email:

Received: 20-May-2026 , Manuscript No. JVV-26-32848; Editor assigned: 22-May-2026 , Pre QC No. JVV-26-32848; Reviewed: 06-Jun-0226 , QC No. JVV-26-32848; Revised: 13-Jun-2026 , Manuscript No. JVV-26-32848; Published: 20-Jun-2026 , DOI: 10.35248/2157-7560.26.17.671

Description

Herd immunity describes a form of indirect protection that occurs when a sufficiently large proportion of a population is immune to an infectious disease. Immunity may develop through vaccination, previous infection, or both. When many individuals are protected, an infectious agent has fewer susceptible people available for transmission, which can reduce the frequency and size of outbreaks [1].

The level of immunity required to limit transmission differs between infectious diseases. Pathogens that spread very efficiently generally require a higher proportion of immune individuals than those with lower transmission rates. This threshold is influenced by factors such as the basic reproduction number, population density, contact patterns, vaccine effectiveness, and the duration of immunity [2].

Vaccination is a major method for increasing population immunity without requiring people to experience the disease itself. When vaccination coverage is high, the probability that an infectious person encounters a susceptible individual can decrease. This can slow transmission and provide indirect protection to people who cannot receive certain vaccines because of age, medical circumstances, or other restrictions.

Herd immunity is particularly relevant for diseases that spread mainly through person-to-person contact. Measles provides a well-known example because it is highly transmissible and requires very high population immunity to prevent sustained transmission. If vaccination coverage decreases in a community, groups of susceptible individuals can accumulate, increasing the likelihood of outbreaks [3].

Population immunity is not evenly distributed. A country may have high overall vaccination coverage while particular communities or age groups have substantially lower coverage. Geographic clustering of susceptible individuals can allow an infectious disease to circulate even when national or regional immunity appears relatively high [4].

The effectiveness of vaccines also affects indirect protection. A vaccine that strongly reduces infection and transmission can contribute more to reducing community spread than one that mainly prevents severe illness. However, vaccines that primarily protect against severe disease can still reduce the overall burden on healthcare systems and decrease serious outcomes among vaccinated individuals [5].

Immunity can change over time. Protection generated by vaccination or infection may decrease, depending on the pathogen and the type of immune response. New variants of a pathogen may also partially escape existing immunity. These factors can alter the level of population protection and may lead public health authorities to recommend additional vaccine doses or updated formulations [6].

Herd immunity should not be confused with complete elimination of an infectious disease. Even when population immunity is high, isolated cases can occur, particularly when an infectious agent is introduced from another region. Maintaining high vaccination coverage and effective disease surveillance can reduce the likelihood that isolated cases develop into larger outbreaks [7].

The concept also has limitations. Natural infection can produce immunity, but obtaining population-level immunity through widespread infection can result in substantial illness, complications, and deaths. For this reason, vaccination is generally preferred as a safer means of increasing immunity against vaccine-preventable diseases [8].

Public understanding also influences population immunity. Misinformation, limited access to healthcare, concerns about vaccine safety, and difficulties obtaining vaccination can contribute to lower coverage. Clear communication about vaccine benefits and risks, convenient vaccination services, and reliable disease surveillance can support higher participation in immunization programs [9].

Herd immunity is therefore a population-level effect produced by individual immune protection. Its strength depends on the infectious disease, the proportion of immune individuals, vaccine performance, duration of protection, and patterns of human contact. Maintaining adequate immunity across communities remains an important strategy for reducing transmission and protecting people who are particularly vulnerable to infectious diseases [10].

Conclusion

Herd immunity highlights the importance of collective responsibility in protecting public health. Individual decisions about vaccination can influence not only personal health but also the safety of the wider community. When vaccination coverage remains consistently high across different population groups, the risk of widespread transmission can be reduced, helping protect infants, older adults, and individuals with weakened immune systems. Continued scientific research, public education, and cooperation between healthcare professionals and communities are essential for strengthening immunization programs. Through these combined efforts, herd immunity can contribute significantly to disease prevention, the reduction of outbreaks, and the long-term improvement of public health.

References

1. Griffin DE. The immune response in measles: virus control, clearance and protective immunity. Viruses. 2016;8(10):282.

   [Google Scholar] [PubMed] [Crossref]

2. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med. 2007;357(19):1903-1915.

   [Google Scholar] [PubMed] [Crossref]

3. Springer DN, Borsodi C, Camp JV, Redlberger-Fritz M, Holzmann H, Kundi M, et al. Seroprevalence against measles, Austria, stratified by birth years 1922 to 2024. Euro Surveill. 2025;30(16):2400684.

   [Google Scholar] [PubMed] [Crossref]

4. Guerra FM, Bolotin S, Lim G, Heffernan J, Deeks SL, Li Y, et al. The basic reproduction number (R0) of measles: a systematic review. Lancet Infect Dis. 2017;17(12):420-428.

   [Google Scholar] [PubMed] [Crossref]

5. Wallinga J, Levy-Bruhl D, Gay NJ, Wachmann CH. Estimation of measles reproduction ratios and prospects for elimination of measles by vaccination in some Western European countries. Epidemiol Infect. 2001;127(2):281-95.

   [Google Scholar] [PubMed] [Crossref]

6. O'Connor P, Jankovic D, Muscat M, Ben-Mamou M, Reef S, Papania M, Singh S, Kaloumenos T, Butler R, Datta S. Measles and rubella elimination in the WHO Region for Europe: progress and challenges. Clin Microbiol Infect. 2017;23(8):504-510.

   [Google Scholar] [PubMed] [Crossref]

7. Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making. 2003;23(1):76-82.

   [Google Scholar] [PubMed] [Crossref]

8. Yang L, Grenfell BT, Mina MJ. Waning immunity and re-emergence of measles and mumps in the vaccine era. Curr Opin Virol. 2020;40:48-54.

   [Google Scholar] [PubMed] [Crossref]

9. Peltola H, Davidkin I, Valle M, Paunio M, Hovi T, Heinonen OP, et al. No measles in Finland. The Lancet. 1997;350(9088):1364-1365.

   [Google Scholar] [PubMed] [Crossref]

10. Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Preblud SR, et al. Measles antibody: reevaluation of protective titers. J Infect Dis. 1990;162(5):1036-1042.

    [Google Scholar] [PubMed] [Crossref]